Author

M Durheim

Institution: Duke Clinical Research Institute

Observed institution: Duke Clinical Research Institute

OpenAlex ID: A5136361551

Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial

2026 · Justin M Oldham, Arata Azuma, et al. · American Journal of Respiratory and Critical Care Medicine · 8

C39-12 Risk of Progressive Pulmonary Fibrosis Among Patients With Systemic Autoimmune Rheumatic Diseases in a Multi-center Real-world Cohort

2026 · M Durheim, S Stevens, et al. · American Journal of Respiratory and Critical Care Medicine

B77-16 Antifibrotic Drug Use Influences the Association Between Pro-C3 and Risk of Mortality or Disease Progression in Patients With Idiopathic Pulmonary Fibrosis

2026 · M Durheim, C Page, et al. · American Journal of Respiratory and Critical Care Medicine

D23-06 Characteristics and Disease Progression Among Patients With Progressive Fibrotic Hypersensitivity Pneumonitis: Findings From the ILD-PRO Registry

2026 · M Durheim, A C Swaminathan, et al. · American Journal of Respiratory and Critical Care Medicine

Works count: 4

Citation count: 8

H-index: 1

I10-index: